Objective: To evaluate emergency physician (EP) attitudes toward smallpox vaccination, the treatment of patients with suspected smallpox, and the threat of a bioterrorist attack.

Methods: This was a prospective study utilizing a standardized survey instrument that was distributed on November 16, 2002, and collected by February 1, 2003. EPs from a sample of 50 accredited emergency medicine programs were surveyed regarding their perspectives on smallpox vaccination.

Results: A total of 989 surveys were collected from 42 emergency medicine programs. Of the respondents, 43.4% would currently volunteer for smallpox vaccination. EPs previously vaccinated against smallpox were 1.46 times more likely to volunteer for vaccination (95% CI = 1.14 to 1.93). EPs who believed they were at risk for complications were less than half as likely to volunteer for vaccination. EPs who perceived a significant risk of a bioterrorist attack were 2.7 times more likely to volunteer for the vaccine compared with those who thought the risk was minimal (95% CI = 2.06 to 3.47). Of the respondents, 34.4% believed the risks of the vaccination outweighed the benefits, 33% did not, and 32.6% were unsure.

Conclusions: Currently, fewer than half of EPs surveyed would volunteer for smallpox vaccination. Factors associated with a willingness to be vaccinated include previous smallpox vaccination and the perceived threat of a bioterrorist attack. The variation in EP attitudes toward smallpox vaccination may be due to uncertain risk-to-benefit ratio. The opinions and actions of EPs may be influential on current and future government policy and public opinion.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1553-2712.2003.tb00042.xDOI Listing

Publication Analysis

Top Keywords

smallpox vaccination
24
smallpox
9
vaccination
9
perspectives smallpox
8
attitudes smallpox
8
threat bioterrorist
8
emergency medicine
8
medicine programs
8
volunteer smallpox
8
vaccination eps
8

Similar Publications

Dynamic analysis and optimal control of a hybrid fractional monkeypox disease model in terms of external factors.

Sci Rep

January 2025

Department of Mathematics and Statistics, College of Science, Taif University, P.O. Box 11099, 21944, Taif, Saudi Arabia.

The monkeypox virus (MPXV), which is a member of the Orthopoxvirus genus in the class Poxviridae, is the causative agent of the zoonotic viral infection MPXV. The disease is similar to smallpox, but it is usually less dangerous. This study examines the evolution of the MPXV epidemic in Canada with an emphasis on the effects of control employing actual data.

View Article and Find Full Text PDF

Background: In May, 2022, the first global outbreak of mpox (formerly known as monkeypox) occurred. In response, public health agencies in the UK have made smallpox vaccines available to individuals at the highest risk of infection. With mpox cases still being detected globally, novel tools are required to aid with diagnosis, serosurveillance, and the evaluation of immune responses following infection and immunisation with current and new vaccine candidates.

View Article and Find Full Text PDF

Purpose Of Review: The 2024 mpox outbreak, primarily driven by the possibly more virulent clade Ib strain, prompted the WHO declaring it a public health emergency of international concern (PHEIC) on August 14, 2024. This review provides essential guidance for clinicians managing mpox cases, as it contrasts the features of the 2024 outbreak with those of the 2022 epidemic to support better clinical decision-making.

Recent Findings: The review highlights significant differences between the 2024 and 2022 outbreaks, including total case numbers, demographic distribution, and fatality rates.

View Article and Find Full Text PDF

Monkeypox: a re-emergent virus with global health implications - a comprehensive review.

Trop Dis Travel Med Vaccines

January 2025

Department of Botany and Microbiology, Faculty of Science, Damanhour University, Damanhour, Egypt.

Monkeypox virus (MPXV) is an enclosed, double-stranded DNA virus from the Orthopoxvirus genus, which also contains variola, vaccinia, and cowpox. MPXV, which was once confined to West and Central Africa, has recently had a rebound, spreading beyond its original range since 2017. The virus is distinguished by its unique morphology, which includes an oval or brick-shaped structure and a complex lipid and protein makeup.

View Article and Find Full Text PDF

Examining homology between MPXV and immunogenic VACV-derived peptides.

Vaccine

January 2025

Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:

The mpox virus (MPXV) came to global attention with the 2022 global outbreak. Current vaccination and post-exposure prophylaxis against MPXV consists of live vaccinia whole virus-based vaccines including ACAM2000®, JYNNEOS™, and LC16m8 originally developed against smallpox. Here, we analyzed 152 vaccinia-derived peptides we identified by mass spectrometry for homology with MPXV-1 and MPXV-2 sequences to evaluate their potential relevance to MPXV-specific immunity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!